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Abstract We analyzed the substrate specificity of six human
K1,3-fucosyltransferases (K1,3FUTs) for the 2-aminobenzamide
(2AB)-labelled polylactosamine acceptor, GalL1-4GlcNAcL1-
3GalL1-4GlcNAcL1-3GalL1-4GlcNAc-2AB (3LN-2AB). FUT9
preferentially fucosylated the distal GlcNAc residue of the
polylactosamine chain while the other four K1,3FUT members,
FUT3, FUT4, FUT5 and FUT6, preferentially fucosylated the
inner GlcNAc residue. This indicated that FUT9 exhibits more
efficient activity for the synthesis of Lewis x carbohydrate
epitope (Lex ; CD15; stage-specific embryonal antigen-1 (SSEA-
1)). In contrast, the other four members synthesize more
effectively the internal Lex epitope. FUT7 could not transfer a
fucose to an acceptor which is non-sialylated.
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1. Introduction
The Lewis x (Lex) carbohydrate epitope on the polylactos-
amine chain is detected as stage-speci¢c embryonal antigen-1
(SSEA-1) at the morulae of the mouse embryo [1] and con-
sidered to play an important role in cell-cell interactions [2^4].
Glycolipid having the dimeric Lex or trimeric Lex structure
accumulates in human lung, liver and colon cancer [5^8]. Di-
meric or trimeric Lex is also observed during human embryo-
genesis [9]. These Lex-related structures have been regarded as
onco-fetal antigens.
K1,3-Fucosyltransferases (K1,3FUTs) transfer a fucose
(Fuc) to N-acetylglucosamine (GlcNAc) of a type 2 chain
(GalL1,4GlcNAc) with an K1,3-linkage and comprise an
K1,3FUT family. We have recently cloned a new member of
the K1,3FUT family, FUT9 (Fuc-TIX) [10,11], in addition to
the ¢ve known members, FUT3 (Fuc-TIII), FUT4 (Fuc-TIV),
FUT5 (Fuc-TV), FUT6 (Fuc-TVI) and FUT7 (Fuc-TVII)
[12^20]. FUT3, FUT4, FUT5, FUT6 and FUT9 can synthe-
size the Lex epitope while FUT7 can not. FUT9 is unable to
synthesize the sialyl Lex epitope, while the other ¢ve
K1,3FUTs can [10,11,21].
The FUT9 gene does not cross-hybridize with the other ¢ve
K1,3FUT genes. On a phylogenetic tree of K1,3FUT members
including vertebrate and Caenorhabditis elegans types, there
are four clusters of vertebrate K1,3FUT genes corresponding
to the FUT3-FUT5-FUT6, FUT4, FUT7 and FUT9 gene sub-
families [10]. The FUT9 gene subfamily diverged ¢rst from the
ancestral gene among the K1,3FUT subfamilies.
Mouse has three functional K1,3Fut genes, Fut4, Fut7 and
Fut9, corresponding to human FUT4, FUT7 and FUT9 genes
[11,22,23]. Of the three functional mouse K1,3Futs, only Fut9
has a very highly conserved amino acid sequence between
human and mouse and the level of conservation is equal to
that of K-actin, suggesting a strong selective pressure for the
preservation of the FUT9 (Fut9) sequence during evolution
[10].
In the present study, we analyzed the FUT activity of re-
combinant enzymes directed by the six K1,3FUT genes for a
neutral polylactosamine acceptor. FUT9 exhibited a com-
pletely di¡erent speci¢city of Fuc transfer to GlcNAc residues
from the other four K1,3FUTs.
2. Materials and methods
2.1. Preparation of oligosaccharide acceptor substrate
The structure of polylactosamine (Fig. 1a) was prepared as an ac-
ceptor substrate by the method described by Tawada et al. [24].
Brie£y, puri¢ed keratan sulfate (KS) (Seikagaku Corporation, Tokyo,
Japan) was partially desulfated by the methanol-HCl method [25]
and digested with keratanase II (Seikagaku Corporation, Tokyo,
Japan). KS-derived oligosaccharides were desulfated completely and
applied to gel ¢ltration columns of cellulo¢ne GCL-90-sf and cel-
lulo¢ne GCL-25-sf to obtain the following two oligosaccalides,
GalL1-4GlcNAcL1-3GalL1-4GlcNAcL1-3GalL1-4GlcNAc (3LN) and
GalL1-4GlcNAcL1-3GalL1-4GlcNAc (2LN). Both oligosaccalides,
whose structures were determined by NMR spectroscopy and mass
spectroscopy, were £uorescently labelled with 2-aminobenzamide
(2AB) according to the manual of the Signal 2AB glycan labelling
kit (Oxford GlycoScience, UK).
2.2. Establishment of Namalwa cells transfected stably with each of six
K1,3FUT genes
In the previous studies, the DNA fragments encoding the full-length
open reading frames of the six human K1,3FUT genes, FUT3, FUT4,
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FUT5, FUT6, FUT7 and FUT9, were subcloned in a pAMo vector
for expression in Namalwa cells [10,26,27]. Stable transformant
cells were then selected using geneticin (1.2 mg/ml) (G418, Sig-
ma).
2.3. Assay of the activity of six K1,3FUTs towards polylactosamine
Stable transformant cells were sonicated in 20 mM HEPES
bu¡er (pH 7.2) containing 1% Triton X-100. Each cell lysate, con-
taining 60 Wg protein, was used for K1,3FUT activity assay in 50 mM
cacodylate bu¡er (pH 6.8), 5 mM ATP, 10 mM L-Fuc, 75 mM
guanosine diphosphate Fuc, 25 mM MnCl2 and 15 mM acceptor
substrate, 3LN-2AB. After incubation at 37‡C for 2 h, the enzyme
reactions were terminated by boiling for 3 min followed by adding
of water. After centrifugation of the reaction mixtures, each super-
natant was ¢ltrated and subjected to reverse-phase high performance
liquid chromatography (HPLC) analysis on a TSKgel ODS-80TS QA
column (4.6U250 mm; Tosoh, Tokyo, Japan) and eluted with a 20
mM ammonium acetate bu¡er (pH 4.0) containing 7% methanol at a
£ow rate of 1.0 ml/min at 50‡C, with monitoring by a £uorescence
spectrophotometer (JASCO FP-920; Nihon Bunkoh, Tokyo, Ja-
pan).
2.4. Puri¢cation of fucosylated polylactosamine
On HPLC analysis using a TSKgel ODS-80TS QA column, the
fraction containing each fucosylated 3LN-2AB was pooled, dried up
and subjected to digestion by exo-glycosidases.
2.5. Digestion of fucosylated polylactosamine by Jack bean
L-galactosidase
Jack bean L-galactosidase digestion of each fucosylated 3LN-2AB
was carried out in a 50 mM sodium citrate bu¡er (pH 3.5) containing
300 mU/ml of Jack bean L-galactosidase (Oxford GlycoScience, UK).
After incubation at 37‡C for 15 h, each digest was concentrated to
dryness, applied to a normal-phase GlycoSep N HPLC column
(4.6U250 mm; Oxford GlycoScience, UK) and eluted with 250 mM
ammonium formate bu¡er (pH 4.4) containing 65% acetonitrile at a
£ow rate of 1.0 ml/min at 30‡C, with monitoring by a £uorescence
spectrophotometer. 2AB-labelled glucose homopolymer standard was
purchased from Oxford GlycoScience (UK).
2.6. Sequential digestion of fucosylated polylactosamine by
exo-glycosidases
Sequential digestion with exo-glycosidases was carried out in a 50
mM sodium citrate bu¡er (pH 5.0) containing an appropriate concen-
tration of each exo-glycosidase, i.e. 0.2 mU/ml of almond meal K1,3/4-
fucosidase (Oxford GlycoScience, UK), 600 mU/ml of Jack bean L-
galactosidase or 10 U/ml of Jack bean L-N-acetylhexosaminidase (Ox-
ford GlycoScience, UK). After incubation at 37‡C for 15 h, each
digest was boiled for 5 min and then centrifuged. An appropriate
amount of each supernatant was subjected to reverse-phase HPLC
analysis using a TSKgel ODS-80TS QA column under the conditions
described above. The remaining supernatant was used for the next
step, digestion by other exo-glycosidases.
Fig. 1. A unique speci¢city of FUT9 for 2AB-labelled polylactosamine acceptor. (a) Top: 3LN-2AB, an oligosaccharide structure of acceptor
substrate used in the present study. Each saccharide residue of the polylactosamine chain is numbered. Below: three expected products of the
enzyme reaction are presented as product A, B and C. (b^d) Reverse-phase HPLC analysis of the reaction products after incubation with
K1,3FUTs. (b) mock reaction, (c) FUT4, (d) FUT9. S, 3LN-2AB; P1, product 1; P2, product 2; P3, product 3.
FEBS 22981 26-11-99
S. Nishihara et al./FEBS Letters 462 (1999) 289^294290
2.7. Assay of the activity of FUT4, FUT6 and FUT9 towards 3LN-2AB
and monofucosylated 3LN-2AB
The enzymatic reactions were performed as described above, except
that 1 mM puri¢ed monofucosylated 3LN-2AB, product A and prod-
uct B, was also used as acceptor substrate (Fig. 1a).
3. Results
3.1. A unique speci¢city of FUT9 for 2AB-labelled
polylactosamine acceptor
Representative HPLC pro¢les of reaction products of the
six human K1,3FUTs are shown in Fig. 1b^d. FUT7 could
not transfer a Fuc to the 2AB-labelled polylactosamine ac-
Fig. 2. Reverse-phase HPLC analysis of the products, product 1 (a), product 2 (b) and product 3 (c), before and after sequential digestion with
almond meal K-fucosidase, Jack bean L-galactosidase and L-N-acetylhexosaminidase. Product 1 (a) was digested by K-fucosidase to obtain a
product whose r.t. was equal to that of 3LN-2AB. Product 2 (b) could not be digested by K-fucosidase and was then digested sequentially with
Jack bean L-galactosidase, L-N-acetylhexosaminidase and K-fucosidase to obtain a product whose r.t. was equal to that of 2LN-2AB. Product
3 (c) was digested by K-fucosidase to obtain a product whose r.t. was equal to that of product 2.
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ceptor, 3LN-2AB. The other ¢ve K1,3FUTs gave three di¡er-
ent products, product 1 (P1), product 2 (P2) and product 3
(P3). FUT9 gave a unique HPLC pro¢le. It produced P1 as a
main peak (Fig. 1d). In contrast, the other four FUTs, i.e.
FUT3, FUT4, FUT5 and FUT6, showed similar HPLC pro-
¢les, synthesizing P2 as a main product (Fig. 1c).
3.2. Assignment of P1, P2 and P3 to the expected fucosylated
polylactosamine structures
Two possible monofucosylated products, products A and B,
and one possible difucosylated product, product C, were ex-
pected to be synthesized by K1,3FUTs (Fig. 1a). To determine
the structure of P1, P2 and P3 (Fig. 1c,d), each peak of P1, P2
and P3 was puri¢ed and applied to a normal-phase HPLC
column. P1 and P2 showed almost the same retention time
(r.t.), 18.8 min (5.8 gu), while P3 gave a slower r.t., 24.9 min
(6.8 gu) (data not shown). The addition of monosaccharide to
oligosaccharide cores usually causes the r.t. to be prolonged
on a normal-phase column [28]. Therefore, P3 was considered
to be most likely the difucosylated product, product C, while
P1 and P2 were considered to be monofucosylated products.
Jack bean L-galactosidase is unable to release a non-reducing
terminal galactose (Gal) residue from the GalL1-4(FucK1-
3)GlcNAc structure [29,30]. Only the puri¢ed P2 peak was
shifted to a decreased r.t. position, 14.5 min (4.9 gu), by
Jack bean L-galactosidase treatment. P1 and P3 were resistant
to it. These results indicated that P1, P2 and P3 in Fig. 1c,d
are products A, B and C in Fig. 1a, respectively.
To ascertain the above assignment, a sequential digestion
with three exo-glycosidases was performed (Fig. 2). Almond
meal K1,3/4-fucosidase releases a Fuc from both GalL1-
3(FucK1-4)GlcNAc- and GalL1-4(FucK1-3)GlcNAc- struc-
tures [31,32]. By treatment with almond meal K1,3/4-fucosi-
dase, the P1 and P3 peaks shifted to the positions of 3LN-
2AB and P2, respectively (Fig. 2a,c). P2 was resistant to it
(Fig. 2b). The digestion with K1,3/4-fucosidase supported the
previous assignment of P1 as product A and P3 as product C
(Fig. 1a). P2 was sequentially digested with three exo-glyco-
sidases (Fig. 2b). The P2 peak shifted from 30.7 min r.t. to
32.1 min r.t. after the terminal Gal (G6) was released by Jack
bean L-galactosidase treatment (Fig. 2b). It shifted from 32.1
min r.t. to 30.0 min r.t. after the GlcNAc residue (GN5) was
released by Jack bean L-N-acetylhexosaminidase treatment
and ¢nally from 30.0 min r.t. to 32.2 min r.t. after the Fuc
residue (F3) was released by K1,3/4-fucosidase treatment. The
¢nal product of P2 after the three glycosidase digestions
showed the same peak, 32.2 min r.t., as that of 2LN-2AB.
This con¢rmed that P2 is a monofucosylated product possess-
ing an internal Fuc (F3), i.e. product B. P3 was ¢rst digested
with K1,3/4-fucosidase and then subjected to sequential diges-
tion by the three glycosidases, as done for P2. The K1,3/4-
fucosidase-digested P3 showed exactly the same pro¢les of
sequential glycosidase digestion as P2 (data not shown).
This con¢rmed that P3 is a difucosylated product, product
C. The above assignment was also con¢rmed by measurement
of the molecular weight of each product by mass spectros-
copy.
There have been no reports of whether almond meal K1,3/4-
fucosidase can digest the internal Fuc or not. The present
Fig. 3. Relative amounts of fucosylated products, product A (P1),
product B (P2) and product C (P3), obtained from enzyme reaction
with each K1,3FUT, i.e. FUT3, FUT4, FUT5, FUT7 and FUT9,
towards the polylactosamine substrate, 3LN-2AB. 1The total
amount of the three products in each enzymatic reaction is 100%.
Fig. 4. Relative FUT activities through two pathways, i.e. via two
monofucosylated 3LN-2AB (product A or product B), leading to
the synthesis of difucosylated 3LN-2AB (product C). The weakest
activity among the pathways in each enzyme reaction, FUT4 (a),
FUT6 (b) and FUT9 (c), is presented as 1.0.
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study demonstrated that almond meal K1,3/4-fucosidase can-
not digest the internal Fuc on polylactosamine chains.
3.3. Preferential activity of six K1,3FUTs for the synthesis of
Lex, internal Lex and dimeric Lex structures
Relative amounts of each product, product A (Lex), prod-
uct B (internal Lex) or product C (dimeric Lex), synthesized
by each of six K1,3FUT enzymatic reactions are shown in Fig.
3. FUT3, FUT4, FUT5 and FUT6 preferentially fucosylated
the inner GlcNAc residue, resulting in the synthesis of prod-
uct B (P2; internal Lex) as a main product. FUT7 could not
synthesize any product. FUT9 preferentially fucosylated the
distal GlcNAc residue on the polylactosamine chain, resulting
in the synthesis of product A (P1; Lex) as a main product.
FUT4, FUT6 and FUT9 could synthesize relatively small
amounts of difucosylated polylactosamine, product C (P3;
dimeric Lex).
3.4. Pathway of difucosylated polylactosamine synthesis by
FUT4, FUT6 and FUT9
To determine the pathway of dimeric Lex synthesis,
K1,3FUT activities of FUT4, FUT6 and FUT9 were assayed
for monofucosylated 3LN-2AB, product A and product B.
The results were summarized in Fig. 4. FUT4 and FUT6
showed higher K1,3FUT activity levels for product A than
product B to synthesize product C, that is, they again prefer-
entially fucosylated the inner GlcNAc residue (GN3) (Fig.
4a,b). In contrast, FUT9 showed stronger K1,3FUT activity
for product B than product A to synthesize product C.
Namely, FUT9 also preferentially fucosylated the distal
GlcNAc residue (GN5) (Fig. 4c).
Supposing that the FUT reaction is a ¢rst-order reaction,
the synthesizing rate for difucosylated product C through
product A, i.e. 1.6U2.8 = 4.5 for FUT4, 2.3U7.6 = 17.5 for
FUT6 and 7.2U1.0 = 7.2 for FUT9, was almost equal to
that through product B, i.e. 4.1U1.0 = 4.1 for FUT4,
16.4U1.0 = 16.4 for FUT6 and 1.6U5.0 = 8.0 for FUT9, re-
spectively. Thus, FUT4, FUT6 and FUT9 synthesize the di-
fucosylated product through both pathways almost at the
same rate.
4. Discussion
In the present study, we demonstrated that the substrate
speci¢city of FUT9 is di¡erent from that of the other
K1,3FUTs. This is rational given that the FUT9 amino acid
sequence is quite di¡erent from those of the other ¢ve
K1,3FUTs which share highly homologous sequences.
The preferential activity to transfer Fuc to the distal
GlcNAc residue by FUT9 suggests that FUT9 synthesizes
the Lex epitope more e⁄ciently in vivo than the other
K1,3FUTs. FUT9 was mainly expressed in neuronal cells in
the central nervous system (CNS), stomach epithelial cells and
peripheral blood leukocytes (PBLs) [10,11]. These tissues were
well investigated by immunohistochemical or £ow cytometri-
cal studies for the expression of the Lex epitope using various
antibodies against Lex. We will examine whether or not the
Lex epitopes of SSEA-1 present during embryogenesis and the
CD15 antigen in the adult CNS, stomach epithelial cells and
PBLs are the products of FUT9.
This is the ¢rst study clarifying the speci¢city towards the
polylactosamine chain of all six human recombinant
K1,3FUTs. Site speci¢cities of recombinant FUT4 and
FUT7 for polylactosamine have been reported [33]. FUT4
preferentially fucosylated inner lactosamine units on both
neutral and K2,3-sialylated polylactosamine chains, whereas
FUT7 preferentially fucosylated the distal lactosamine unit
on the K2,3-sialylated polylactosamine chain. The FUT4 spe-
ci¢city reported by Niemela et al. is consistent with our re-
sults.
Site speci¢cities of human milk FUT(s), which were parti-
ally puri¢ed and likely contained two K1,3FUTs, FUT3 and
FUT6 [34], for neutral and sialylated polylactosamine, have
also been reported [35^37]. They prefer to transfer Fuc to an
internal GlcNAc residue. Our results showing that both FUT3
and FUT6 preferentially fucosylate the internal GlcNAc res-
idue are consistent with the human milk FUT activity.
Site-speci¢c FUT activity for type 2 chain glycosphingolipid
nLc6 has been reported using cell lysates of various cancer cell
lines [5,7,8] and Chinese hamster ovary (CHO) mutant cells
[38]. The cell lysates of Colo205 cells (a colon cancer cell line)
and LEC11 CHO mutant cells exhibit preferential Fuc trans-
fer to the internal GlcNAc residue, while the lysates of PC9
and NCI-H69 cells (lung cancer cell lines) and LEC12 CHO
cells prefer to transfer a Fuc to the distal GlcNAc residue. In
a previous study, the FUT3, FUT4 and FUT6 genes were
found to be expressed in human colorectal cancer tissues
and colorectal cancer cell lines including Colo205 [39]. The
FUT9 gene was not expressed in colorectal tissues and
Colo205 cells (data not shown). Recently, LEC11 cells have
been reported to express the FUT gene orthologous to the
human FUT6 gene [40]. The preferential activity to transfer
Fuc to the internal GlcNAc of Colo205 and LEC11 cell ly-
sates is attributed to FUT3, FUT4 and FUT6, not to FUT9.
PC9, NCI-H69 and LEC12 CHO cells, which exhibited pref-
erential activity to transfer Fuc to the distal GlcNAc, may
express FUT9. In a preliminary experiment, we observed
that PC9 cells expressed a substantial amount of FUT9 tran-
scripts and the PC9 cell lysates preferentially fucosylated the
distal GlcNAc residue of the polylactosamine acceptor.
We tried to construct a molecular model of the polylactos-
amine chain based on the interaction of hydrogen bonds (data
not shown). The tentative model showed a zigzag structure of
the smallest repeating unit, (GalL1-4GlcNavL1-)2. The 3-OH
of the distal GlcNAc residue (GN5) was exposed to solvent,
while the 3-OH of the inner GlcNAc residue (GN3) was some-
what hindered. This zigzag structure of the polylactosamine
backbone is not in£uenced by the fucosylation of GlcNAc
residue. This may be true, because we demonstrated in the
present study that each K1,3FUT showed the similar activity
of Fuc transfer irrespective of whether the acceptor was non-
fucosylated or monofucosylated (Fig. 4). FUT9 and the other
K1,3FUTs cooperatively synthesize the dimeric Lex structure.
Stomach mucosae and PBLs are the tissues expressing both
FUT9 and FUT4 [10], in which the dimeric Lex may be abun-
dantly expressed.
Finally, the products fucosylated by the unique speci¢city
of FUT9, i.e. the preferential Fuc transfer to the distal
GlcNAc, should have speci¢c biological roles di¡ering from
those of the products fucosylated by the other K1,3FUTs.
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